Adam H. Skolnick

Adam H. Skolnick

Auto-generated profile, based on publicly available information

Adam H. Skolnick

Department of Medicine, NYU Langone Medical Center, USA

Research Focus & Metrics

Academic Career Length

19Years (2008-Present)

(Calculated once Scilit publication data is synced: current year − year of first publication + 1)

Representative Publications

View All Publications
1 July 2023 in Hypertension
Verified
Journal Article
Closed access
MMMuhammad Haisum Maqsood
Muhammad Haisum Maqsood
FMFranz H. Messerli
Franz H. Messerli
ASAdam H. Skolnick
Adam H. Skolnick
JNJonathan Newman
Jonathan Newman
JBJeffrey S. Berger
Jeffrey S. Berger
SBSripal Bangalore
Sripal Bangalore
Background: The timing of antihypertensive drugs administration is controversial. The aim was to compare the efficacy of dosing of antihypertensive drugs in the morning versus evening. Methods: A PubMed, EMBASE, and clinicaltrials.gov databases search for randomized clinical trials of antihypertensive therapies where patients were randomized to morning versus evening dosing. The outcomes were ambulatory blood pressure (BP) parameters (day-time, night-time, and 24/48-hour systolic blood pressure [SBP] and diastolic blood pressure [DBP]) and cardiovascular outcomes. Results: Of 72 randomized controlled trials included, evening dosing significantly reduced ambulatory BP parameters: 24/48-hour SBP (mean difference [MD]=1.41 mm Hg; [95% CI, 0.48–2.34]), DBP (MD=0.60 mm Hg [95% CI, 0.12–1.08]), night-time SBP (MD=4.09 mm Hg [95% CI, 3.01–5.16]), DBP (MD, 2.57 mm Hg [95% CI, 1.92–3.22]), with a smaller reduction in day-time SBP (MD=0.94 mm Hg [95% CI, 0.01–1.87]), and DBP (MD=0.87 mm Hg [95% CI, 0.10–1.63]), and numerically lower cardiovascular events compared with morning dosing. However, when controversial data by Hermida (23 trials, 25 734 patients) were omitted ( P heterogeneity <0.05 for most outcomes), the above effect of evening dosing attenuated with no significant effect on 24/48-hour ambulatory blood pressure, day-time BP, and major adverse cardiac event and smaller reduction in night-time ambulatory SBP and DBP. Conclusions: Evening dosing of antihypertensive drugs significantly reduced ambulatory BP parameters and lowered cardiovascular events but the effect was mainly driven by trials by Hermida group. Unless the intention is to specifically lower night-time BP, antihypertensive drugs should be taken at a time of day that is convenient, optimizes adherence, and minimizes undesirable effects.

5 August 2008 in Annals of Internal Medicine
Verified
Journal Article
Closed access
PDF file
BBBenjamin R. Bergman
Benjamin R. Bergman
HRHarmony R. Reynolds
Harmony R. Reynolds
ASAdam H. Skolnick
Adam H. Skolnick
DCDemetrio Castillo
Demetrio Castillo

15 July 2025 in JACC: Case Reports
Verified
Journal Article
Open access
DLDalia Littman
Dalia Littman
JLJessica Lovett
Jessica Lovett
AAAndrew Adelsheimer
Andrew Adelsheimer
MBMichelle Bloom
Michelle Bloom
DKDavid Kaminetzky
David Kaminetzky
ASAdam H. Skolnick
Adam H. Skolnick
Extrinsic compression of the pulmonary artery (PA) has been described with mediastinal and other thoracic masses. This compression can lead to acquired pulmonic stenosis and pulmonary hypertension. A 27-year-old woman was diagnosed with Hodgkin lymphoma with a mediastinal mass compressing her PA leading to severe pulmonary hypertension, without hemodynamic compromise. She was treated with chemotherapy and had rapid resolution of the pulmonary artery compression on subsequent transthoracic echocardiogram 1 month after starting treatment. The current literature on the rare entity of extrinsic PA compression includes cases of surgical or percutaneous intervention to relieve compression and cases with resolution of compression based on changes in physical examination or transthoracic echocardiogram several months after initial diagnosis. This case is novel in reporting echocardiographic evidence of complete resolution of PA compression within 1 month of treatment without invasive intervention. Pulmonary hypertension secondary to extrinsic PA compression from a mediastinal tumor is rare, but this case demonstrates that it may completely and rapidly resolve after initiation of chemotherapy. Short-interval follow-up echocardiography is helpful to reassess the degree of pulmonary hypertension after treatment.

12 October 2026 in JACC: Case Reports
Verified
Journal Article
Open access
SZSophia Zhou
Sophia Zhou
MBMichelle Bloom
Michelle Bloom
DWDavid R. Wise
David R. Wise
CGCaroline T. Goldberg
Caroline T. Goldberg
MEMinas Economides
Minas Economides
ASAdam H. Skolnick
Adam H. Skolnick
Renal cell carcinoma (RCC) accounts for 3% of solid malignancies, with clear cell RCC (ccRCC) comprising 80% of cases. Although 20%-30% of RCC cases are metastatic at diagnosis, cardiac metastases are rare. A 65-year-old man with a remote history of ccRCC developed progressive dyspnea. Evaluation showed pulmonary nodules and a fluorodeoxyglucose-avid left ventricular mass. Surgical resection confirmed ccRCC. He received dual immune checkpoint inhibitor therapy and achieved a complete response. His treatment was complicated by pneumonitis, which resolved with corticosteroids. He remains in remission off therapy. This is a rare case of oligorecurrent RCC with cardiac metastasis without inferior vena cava involvement after prolonged remission. It emphasizes the complexity of decision-making because of extracardiac metastasis and treatment complications. Cardiac metastasis is rare in oligorecurrent RCC, but relapse may occur even after prolonged latency periods. Appropriate treatment requires identification of other metastatic sites and a multidisciplinary approach.

31 May 2019
Verified
Dataset
Closed access
ASAdam Skolnick
Adam Skolnick
One of the most consequential decisions cardiologists make among patients after percutaneous coronary intervention (PCI) is whether to interrupt or discontinue dual anti-platelet therapy (DAPT). It is known that older adults have a higher risk of both ischemic events (death, myocardial infarction, stent thrombosis, or target lesion revascularization) and major bleeding. This important study by Joyce et al. seeks to clarify the magnitude of risk stratified by age group. They used the PARIS database, from a prospective observational study of patients who discontinued (physician-advised), interrupted (physician-advised) or disrupted (due to patient non-compliance or bleeding) DAPT stratified by age ≤55, 56-74, and ≥75 years. Discontinuation of DAPT was associated with a lower risk of major ischemic events across all ages, while interruption had no effect on ischemic event rates. Disruption of DAPT demonstrated an increased risk of cardiovascular ischemic events only in the youngest age group. This study suggests that among younger patients, the benefit of DAPT to prevent ischemic events is significant whereas the benefit in older adults is somewhat lower. It suggests that disruption of DAPT in the face of bleeding in older adults may be the preferred strategy among older adults, but should be used with even greater caution in younger populations. These results support a prospective trial using differential strategies of DAPT stratified by age to confirm these findings.

28 August 2020
Verified
Dataset
Closed access
ASAdam Skolnick
Adam Skolnick
The SARS-CoV-2 pandemic has ravaged the world, with each nation having developed its own mitigation strategies. The rates of infection in New York City and Europe are now extremely low, and it has been theorized that this is due to effective herd immunity from pre-existing T cell memory to similar viruses. This excellent study by Mateus et al. analyzes human blood samples derived from 2019 and demonstrates 142 T cell epitopes that show cross-reactivity with SARS-CoV-2. The authors suggest that up to 50% of people may have pre-existing T cell memory to SARS-CoV-2. If 50% of the population already has T cell memory-induced immunity to SARS-CoV-2, it would suggest that only ~25% of a population needs to develop a true antibody response for the entire population to develop effective herd immunity (~75% effectively cannot be infected). This suggests that hard-hit areas like New York City and Northern Italy now have effective herd immunity with extremely low rates of COVID-19 despite only one-quarter of the population with detectable neutralizing antibodies. This study has profound implications for the public health approach to combating COVID-19.